Efficacy and Safety of AQX-1125 in IC/BPS
Status: | Completed |
---|---|
Conditions: | Other Indications, Psychiatric, Urology, Urology |
Therapuetic Areas: | Nephrology / Urology, Psychiatry / Psychology, Other |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 4/21/2016 |
Start Date: | June 2013 |
End Date: | June 2015 |
A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway
The primary objective of this study is to evaluate the effect of 6 weeks of treatment with
once daily administration of AQX-1125 compared to placebo on average daily pain in subjects
with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using
a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary
once daily administration of AQX-1125 compared to placebo on average daily pain in subjects
with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using
a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary
Inclusion Criteria:
- Be females, ≥18 and ≤75 years of age who have consistently had symptoms of bladder
pain in addition to urinary urgency and/or urinary frequency for more than 12 months
- Have had the diagnosis of interstitial cystitis for > 6 months (but pain for at least
12 months) but ≤15 years
- Have average daily pain score of at least 5 out of 10 on the 11-point NRS pain scale
in the 7 days prior to baseline
- Have undergone a cystoscopy and have documented visible signs of bladder bleeding,
lesions or glomerulation within the last 36 months prior to baseline.
- Subjects if of child bearing potential, must agree to avoid pregnancy and use
medically acceptable method of contraception from screening visit and throughout the
study.
- Must be capable of voiding independently
Exclusion Criteria:
- Pelvic floor pain (>5 out of 10 on the 11-point NRS pain scale following a pelvic
pain assessment)
- Have a body mass index [BMI] of <18 kg/m2 or >39 kg/m2
- Have had a urinary tract infection including bacterial cystitis within the past 30
days.
- Have greater than 1+ hematuria on dipstick test at screening from an unknown cause
- History of previous procedure(s) (augmentation cystoplasty, cystectomy, or
cystolysis) that has affected bladder function
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials